

ANALGESICS, OPIOID LONG-ACTING PRIOR AUTHORIZATION FORM (form effective 7/10/2023)

Prior authorization guidelines for **Analgesics**, **Opioid Long-Acting** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx.

. mammady donned mode	no at mtps://www.ans.pa.c	TO THE CHARLES		ad cor a craanta cort		
□ New request □ Renewal request	# of pages:	Prescriber name:				
Name of office contact:		Specialty:				
Contact's phone number:		NPI:		State license #:		
LTC facility contact/phone:		Street address:				
Beneficiary name:		City/state/zip:				
Beneficiary ID#:	DOB:	Phone: Fax:		Fax:		
CLINICAL INFORMATION						
Drug requested:	Strength:		Formul	Formulation (capsule, tablet, etc.):		
Directions:		Weight (if <21 years of age):				
			Dogwood duratio			
Quantity per fill:	days	Requested duration:				
Diagnosis (submit documentation):		Dx code (required	de (<u>required</u>):			
 Pennsylvania law requires prescribers to query the <u>PA PDMP</u> each time a patient is prescribed an opioid drug product or benzodiazepine. 						
 Naloxone is available at Pennsylvania pharmacies via standing order from the Secretary of the Department of Health. Pennsylvania Medical Assistance beneficiaries may obtain naloxone <u>free-of-charge</u> through their prescription drug benefit. 						
Complete all sections that apply to the beneficiary and this request.						
Check all that apply and <u>submit documentation</u> for each item.						
INITIAL requests						
1. For a <u>non-preferred</u> Analgesic, Opioid Long-Acting (See the Preferred Drug List for the list of preferred and non-preferred Analgesics, Opioid Long-Acting at: https://papdl.com/preferred-drug-list): [For a non-preferred product containing buprenorphine :						
Tried and failed or has a contraindication or an intolerance to the preferred Analgesics, Opioid Long-Acting containing <u>buprenorphine</u>						
For a non-preferred product containing <u>tramadol</u> : Tried and failed or has a contraindication or an intolerance to the preferred Analgesics, Opioid Long-Acting containing <u>tramadol</u>						
For all other non-preferred Analgesics, Opioid Long-Acting:						
☐ Tried and failed or has a contraindication or an intolerance to the preferred Analgesics, Opioid Long-Acting						
2. For a beneficiary with a concurrent prescription for a buprenorphine agent indicated for the treatment of opioid use disorder (OUD) OR Vivitrol (naltrexone extended-release suspension for injection):						
☐Both prescriptions are prescribed by the same prescriber						
	□ Prescriptions are prescribed by different prescribers and all prescribers are aware of the other prescription(s)□ Not applicable – beneficiary is not taking a buprenorphine agent indicated for the treatment of OUD or Vivitrol					



3.	For <u>all</u> Analgesics, Opioid Long-Acting:									
	☐ Has a diagnosis of active cancer, sickle cell with crisis, or neonatal abstinence syndrome → submit request to DHS									
	☐ Is receiving palliative care or hospice services → submit request to DHS									
	Has documentation of pain that is all of the following:									
	Caused by a medical condition									
	☐ Not migraine in type									
	Severe									
☐ Tried and failed or has a contraindication or an intolerance to non-opioid analgesics appropriate for the beneficiary's condition: ☐ acetaminophen ☐ duloxetine (e.g., Cymbalta, Drizalma)										
						gabapentinoids (e.g., gabapentin, pregabalin [Lyrica])				
						□NSAIDs (e.g., ibuprofen, naproxen, meloxicam, etc.)				
	☐ tricyclic antidepressants (e.g., amitriptyline, nortriptyline, etc.)									
	Other (specify):									
	Has documentation of a trial of short-acting opioids	man/haur augandana 20 ma/dag aral								
	Is opioid-tolerant (for adults, is defined as taking at least morphine 60 mg/day, transdermal fentanyl 25 hydromorphone 8 mg/day, or an equianalgesic dose of another opioid for one week or longer)	ncg/nour, oxycodone 30 mg/day, orai								
	Was assessed by the prescriber for the potential risk of opioid misuse or opioid use disorder									
	Has results of a recent urine drug screen (UDS) testing for licit and illicit drugs with the potential for abu	se including specific testing for								
	oxycodone, fentanyl, buprenorphine, and tramadol, that is consistent with prescribed controlled substar	0 .								
		1003								
4.	For a beneficiary with a concurrent prescription for a benzodiazepine:									
	The benzodiazepine is being tapered									
	The opioid is being tapered									
	Concomitant use of the benzodiazepine and opioid is medically necessary Not applicable – beneficiary is not taking a benzodiazepine									
	RENEWAL requests									
_	·									
1.	For <u>all</u> Analgesics, Opioid Long-Acting:	546								
☐ Has a diagnosis of active cancer, sickle cell with crisis, or neonatal abstinence syndrome → submit request to DHS										
	□ Is receiving palliative care or hospice services → submit request to DHS	on.								
	Experienced an improvement in pain control and/or level of functioning while on the requested medicati									
	Has results of a recent urine drug screen (UDS) testing for licit and illicit drugs with the potential for abu	5 .								
oxycodone, fentanyl, buprenorphine, and tramadol, at least every 12 months that is consistent with prescribed controlled substances										
2.	For a beneficiary with a concurrent prescription for a benzodiazepine:									
	The benzodiazepine is being tapered									
	The opioid is being tapered									
	Concomitant use of the benzodiazepine and opioid is medically necessary									
	Not applicable – beneficiary is not taking a benzodiazepine									
	PLEASE <u>FAX</u> COMPLETED FORM WITH <u>REQUIRED CLINICAL DOCUMENTATION</u> TO DHS – PHARMACY DIVISION									
Pres	scriber Signature:	Date:								

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.